1. Home
  2. BGNE

BGNE

BeiGene Ltd.

Logo BeiGene Ltd.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-22-2024 3:30pm EST

$
-
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.

Founded: 2010 Country:
United States
United States
Employees: N/A City: GRAND CAYMAN
Market Cap: 16.1B IPO Year: 2016
Target Price: $256.26 AVG Volume (30 days): 248.9K
Analyst Decision: Buy Number of Analysts: 9
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.65 EPS Growth: N/A
52 Week Low/High: $132.95 - $270.57 Next Earning Date: 05-02-2024
Revenue: $2,458,779,000 Revenue Growth: 73.65%
Revenue Growth (this year): 793.94% Revenue Growth (next year): 31.96%

Share on Social Networks: